Building a company from scratch to a multi-million dollar venture is not an easy walk in the park, and if you doubt, ask Clay Siegal. It requires sacrifice, wisdom and tolerance. Clay Siegal has built Seattle Genetics from a small startup into one of the most popular cancer research centers in the United States. The company has attracted a lot of investors due to its exemplary performance. It recently received more than $300 million funding to boost its scope of operations and expand its service portfolio.
Clay Siegal has a passion for genetic research. He pursued a degree in biotechnology to help him build a foundation in genetic research. He later went to do his masters and Ph.D in the same line of study. With energy and zeal to conquer the field of medicine, he co-founded Seattle Genetics in 1998. Siegall is now the CEO and a member of the Board of Directors. He has guided the company through thick and thin in the world of research. The company specializes in producing cancer drugs. Some of its drugs have already been tested by relevant authorities and approved for use in the whole country.
Clay Siegall’s dream is to make a difference in cancer research. He hopes that one day his company will come up with a drug that eradicates the abnormal cells completely from the body. He is currently working on new drugs that will help in treating bladder and liver cancers. Its drug Adcetris is already in the hospitals, and it is used to treat various types of lymphomas.
Before he founded Seattle Genetics, Clay Siegall worked in other companies such as Bristol Myers Squib, National Cancer Institute and Biomedical Association. He is a board member at Fred Hutchison and Washington Biotechnology. In 2013, he was appointed the chairman of the Board of Directors at Mirna Therapeutics Inc., a company that produces microRNAs. His commitment to ensuring people get solutions to their health problems, especially cancer, has made him a popular figure. His company is also a leading brand that is known for producing quality drugs. Siegall graduated from Maryland and Washington University where he did his degree and Ph.D. respectively.
Seattle Genetics is the fastest growing cancer research Center in the United States. The company’s only commercialized drug Adcetris has made the company even more famous, earning it profits of up to $226 million. Adcetris is commonly used to fight lymphomas and is currently being tested against various types of lymphomas. With Takeda Pharmaceuticals, Seattle’s partner company, trying to sell Adcetris outside Canada and the United States, profits accrued are expected to increase.
Seattle Genetics big plans
Adcetris is not the only drug developed by Seattle Genetics; the firm is developing other 12 cancer-fighting drugs. According to Seattle Genetics CEO, the company plans to introduce another drug, 33A, into phase 3 clinical trials. The drug is expected to treat acute myeloid leukemia. The company is also finalizing the development of three other drugs: two are used to treat cancer of the bladder and one that treats breast cancer.
Seattle Genetics has major plans; aside from introducing new drugs, the company plans to increase their workforce. It estimated that 100 people would be hired in the United States branches and 20 in Switzerland, making it 120 people. Seattle Genetics already has 800 employees – increase in the workforce will result in an increase in annual output.
Dr. Clay Siegall obtained his bachelor’s degree in Zoology from the University of Maryland and his doctoral degree in genetics from George Washington University. Dr. Siegall is the founder and the CEO of Seattle Genetics since 1998. He is also part of the board of directors of Seattle Genetics. Dr. Siegall educational background clearly states that he is a trained researcher and his primary interest is in cancer therapies. Therefore, he has capitalized on his professional expertise to develop antibody-drug conjugates (ADC’s) for treatment of cancer.
Dr. Siegall has over the years served as a director of the board of directors for various companies such as Ultragenyx Pharmaceuticals, Mirna Therapeutics, Inc., and Alder Biopharmaceuticals Inc. Before Seattle Genetics was formed, he used to work for Bristol-Myers Squibb Pharmaceutical Research Institute. He also worked for the National Cancer Institute and National Institutes of Health. With his work experience, he has been able to run activities at Seattle Genetics smoothly.
Mirna Therapeutics announced their intentions to appoint Clay Siegall to their Board of Directors. Mirna Therapeutics was founded in 2007 and is based in Austin, Texas. The company’s focus is on microRNA in therapeutics. Dr. Siegall has previous experience in cancer research, and that is what the company is currently dealing with. The company’s CEO expects guidance from Dr. Siegall in the development of microRNA therapeutics.
Seattle Genetics as a biotechnological company develops clinical and preclinical products. Its foundation is on extensive research, scientific modification, and drug enhancement. Since its establishment in 1998, the company has developed and availed antibody-drug conjugate (ADC) which is used in cancer treatment. The drug is available in the market and is approved in over 60 countries. The ADC technology reduces the negative effects of chemotherapy while improving antitumor activity in the body. There are various types of ADCs and they are used for different purposes. Siegall Genetics Company is headquartered in Bothell Washington. It partners with many companies and has licenses with many others.
Clay Siegall studied Zoology at the University of Maryland. Later, he received his Ph.D. in Genetics from George Washington University. He then worked in different places such as the National Cancer Institute, the National Institute of Health and the Bristol-Myers Squibb-A pharmaceutical research institute before he co-founded Seattle Genetics. Clay Siegall is the Chairman of the Board of Directors, Chief Executive Officer of Seattle Genetics Company. He is also a board member of Alder Pharmaceuticals Inc., the Washington Biotech, Ultragenyx Pharmaceuticals, and Biomedical Association and Fred Hutchinson Cancer Research Centre.
Clay strives to take care of the unsolved medical needs in oncology. He may be the one to come up with the drug to cure cancer. Siegall has written more than 70 publications and had 15 patents. He also has various awards including the Alumnus of the Year for Computer, Math and Natural Sciences from the University of Maryland in 2013 and the Entrepreneur of the Year from Pacific Northwest from Earnest and Young in 2012. Dr. Siegall has also led in fundraising for Seattle Genetics through both public and private financing.